Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held Oct. 8-10 in Porto, Portugal. The event served as a platform for the company to showcase GelrinC(R), its CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes.
Surgeon interest in GelrinC is significant because it underscores the medical community's recognition of a potential paradigm shift in cartilage repair. Current treatments for knee cartilage damage often involve invasive procedures with lengthy recovery times and unpredictable outcomes. GelrinC offers an off-the-shelf, cell-free solution that can be implanted in a short, single procedure, potentially improving patient outcomes and reducing healthcare burdens. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) scores compared with historical microfracture controls at two years, with subsequent MRI analyses showing results consistent with durable, native-like cartilage regeneration. These clinical results, combined with the practical advantages of a 10-minute procedure, are likely driving the strong surgeon engagement reported at the summit.
The implications of this announcement extend beyond the immediate interest shown by physicians. Regentis is working to translate that interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. If the pivotal trial succeeds, GelrinC could become the first off-the-shelf treatment for knee cartilage repair in the U.S., addressing a market of approximately 470,000 cases annually where no such option currently exists. This would not only provide a new revenue stream for Regentis but also offer a much-needed solution for patients suffering from knee cartilage damage, potentially delaying or preventing the need for more invasive surgeries like total knee replacement.
For investors, the strong surgeon interest at the ICRS Summit signals growing validation of GelrinC's clinical and commercial potential. With a CE Mark in Europe and a pivotal trial underway in the U.S., Regentis is positioning itself at the forefront of regenerative orthopedics. The company's Gelrin platform technology, based on synchronized, degradable hydrogel implants, could also be applied to other tissue repair applications beyond cartilage, opening additional long-term opportunities. As Regentis continues to engage with the medical community and expand its European Centers of Excellence, the momentum from the ICRS Summit could accelerate the adoption curve and strengthen the company's market position.
To view the full press release, visit https://ibn.fm/hcEu4. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. InvestorWire, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of social media followers. For more information, please visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
